While our current study primarily focuses on the role of the Tau–GCs interaction in bone resorption and the efficacy of TRx0237 in preventing dexamethasone-induced bone loss, we recognize that GCs are associated with a variety of side effects, including insulin resistance, high blood glucose, disorders of lipid metabolism, myopathy, and immunosuppression. The gene discussed is MAPT; the disease is myopathy.